Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
3-D Matrix, Ltd. is a Japan-based biotechnology and medical device company focused on regenerative medicine and surgical hemostasis solutions. The company develops and commercializes synthetic self-assembling peptide technologies used primarily in medical devices and regenerative medicine research, serving hospitals, surgeons, and research institutions. Its flagship commercial product is PuraStat, a synthetic peptide-based hemostatic agent used to control bleeding during surgical and endoscopic procedures, which represents the company’s primary revenue driver.
Founded in 2001 as a university spin-out, the company originated from research conducted by its scientific founder on peptide nanofiber technology. Over time, 3-D Matrix, Ltd. transitioned from a research-centric organization into a commercial-stage company, achieving regulatory approvals in multiple regions and expanding its product applications beyond research use into clinical and surgical settings. The company is publicly listed in Japan and its shares also trade in the U.S. via the OTC market under the ticker DMTRF.
Business Operations
The company operates through two principal business activities: Medical Device Business and Regenerative Medicine Research & Development. The Medical Device Business generates the majority of revenue through sales of PuraStat and related peptide-based hemostatic products, which are marketed to hospitals and medical providers for use in gastrointestinal, cardiovascular, and general surgical procedures. Revenue is generated through direct sales and distribution partnerships, particularly outside Japan.
The Regenerative Medicine R&D activity focuses on the development of peptide scaffolds for tissue regeneration and cell culture applications. This segment includes research collaborations and early-stage development programs rather than large-scale commercial sales. The company operates through key subsidiaries including 3-D Matrix Europe SAS and 3-D Matrix USA Inc., which support regional commercialization, regulatory activities, and clinical engagement.
Strategic Position & Investments
3-D Matrix, Ltd. positions itself as a specialized provider of fully synthetic, animal-free peptide technologies, which differentiates its products from biologically derived hemostatic agents. Its strategic focus centers on expanding the clinical indications and geographic adoption of PuraStat, particularly in minimally invasive and endoscopic procedures where bleeding control is critical. Growth initiatives emphasize regulatory approvals, reimbursement expansion, and increased penetration in existing hospital customers.
The company has historically invested in internal research rather than large-scale acquisitions, prioritizing proprietary technology development and clinical validation. Notable investments include continued development of next-generation peptide formulations and exploratory applications in wound healing and tissue regeneration. Data inconclusive based on available public sources regarding material acquisitions or equity investments in external portfolio companies beyond wholly owned operating subsidiaries.
Geographic Footprint
The company is headquartered in Japan, with its principal operations and corporate functions located there. Commercial activities extend across Europe, North America, and parts of Asia, supported by its regional subsidiaries and distribution partners. Europe represents a significant market due to early regulatory approvals and adoption of PuraStat in endoscopic procedures.
Through 3-D Matrix Europe SAS and 3-D Matrix USA Inc., the company maintains an operational presence in France and the United States, enabling closer engagement with regulators, clinicians, and distributors. While Japan remains the core operational base, international markets account for a growing share of commercial activity and strategic focus.
Leadership & Governance
The company was founded by Kiyotaka Shiba – Scientific Founder, whose academic research underpins its core peptide technology. Executive leadership is responsible for balancing commercialization of approved products with continued investment in regenerative medicine research. Public disclosures emphasize disciplined capital allocation and a long-term strategy centered on clinical evidence and regulatory compliance.
Key executives include:
- Toshiaki Suzuki – President & Chief Executive Officer
- Kiyotaka Shiba – Founder & Director
- Kenji Akuta – Director
- Hiroshi Yamada – Executive Officer
Data inconclusive based on available public sources regarding detailed leadership philosophy statements beyond general commitments to innovation, patient safety, and global expansion.